Genmab A/S (NASDAQ:GMAB) Research Coverage Started at Wolfe Research

Wolfe Research assumed coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note issued to investors on Friday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $32.00 target price on the stock.

GMAB has been the topic of a number of other research reports. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. HC Wainwright upped their price target on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wells Fargo & Company began coverage on Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective on the stock. Finally, Guggenheim cut their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.36.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $25.82 on Friday. The company’s 50 day moving average is $29.40 and its 200-day moving average is $30.49. The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $35.43. The firm has a market cap of $16.59 billion, a price-to-earnings ratio of 16.66, a P/E/G ratio of 1.06 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. boosted its position in shares of Genmab A/S by 472.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 12,572 shares of the company’s stock valued at $387,000 after acquiring an additional 10,376 shares in the last quarter. Corient Private Wealth LLC increased its stake in Genmab A/S by 10.9% in the fourth quarter. Corient Private Wealth LLC now owns 17,469 shares of the company’s stock valued at $538,000 after acquiring an additional 1,724 shares during the period. MidFirst Bank acquired a new position in Genmab A/S in the fourth quarter worth about $56,000. DGS Capital Management LLC raised its position in Genmab A/S by 116.5% in the fourth quarter. DGS Capital Management LLC now owns 18,203 shares of the company’s stock worth $561,000 after purchasing an additional 9,795 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Genmab A/S during the fourth quarter worth about $697,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.